HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Supplementary Figure Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (12) Citing Articles via Google Scholar Google Scholar Articles by Zhong, L. Articles by Ng, Y.-S. Search for Related Content PubMed PubMed Citation Articles by Zhong, L. Articles by Ng, Y.-S.

Erythropoietin Promotes Survival of Retinal Ganglion Cells in DBA/2J Glaucoma Mice

¹From (OSI) Eyetech, Inc., Lexington, Massachusetts; and the ²Massachusetts Eye and Ear Infirmary, Boston, Massachusetts.

PURPOSE. Retinal ganglion cell (RGC) loss occurs in response to increased intraocular pressure (IOP) and/or retinal ischemia in glaucoma and leads to impairment of vision. This study was undertaken to test the efficacy of erythropoietin (EPO) in providing neuroprotection to RGCs in vivo.

METHODS. The neuroprotective effects of EPO were studied in the DBA/2J mouse model of glaucoma. Mice were intraperitoneally injected with control substances or various doses of EPO, starting at the age of 6 months and continuing for an additional 2, 4, or 6 months. RGCs were labeled retrogradely by a gold tracer. IOP was measured with a microelectric-mechanical system, and EPO receptor (EPOR) expression was detected by immunohistochemistry. Axonal death in the optic nerve was quantified by para-phenylenediamine staining, and a complete blood count system was used to measure the number of erythrocytes.

RESULTS. In DBA/2J mice, the average number of viable RGCs significantly decreased from 4 months to 10 months, with an inverse correlation between the number of dead optic nerve axons and viable RGCs. Treatment with EPO at doses of 3000, 6000, and 12,000 U/kg body weight per week all prevented significant RGC loss, compared with untreated DBA/2J control animals. EPO effects were similar to those of memantine, a known neuroprotective agent. IOP, in contrast, was unchanged by both EPO and memantine. Finally, EPOR was expressed in the RGC layer in both DBA/2J and C57BL/6J mice.

CONCLUSIONS. EPO promoted RGC survival in DBA/2J glaucomatous mice without affecting IOP. These results suggest that EPO may be a potential therapeutic neuroprotectant in glaucoma.

This article has been cited by other articles:

				W. A. Hare and L. Wheeler Experimental Glutamatergic Excitotoxicity in Rabbit Retinal Ganglion Cells: Block by Memantine Invest. Ophthalmol. Vis. Sci., June 1, 2009; 50(6): 2940 - 2948. [Abstract] [Full Text] [PDF]

				W.-K. Ju, K.-Y. Kim, M. Angert, K. X. Duong-Polk, J. D. Lindsey, M. H. Ellisman, and R. N. Weinreb Memantine Blocks Mitochondrial OPA1 and Cytochrome c Release and Subsequent Apoptotic Cell Death in Glaucomatous Retina Invest. Ophthalmol. Vis. Sci., February 1, 2009; 50(2): 707 - 716. [Abstract] [Full Text] [PDF]

				M. Garcia-Ramirez, C. Hernandez, and R. Simo Expression of Erythropoietin and Its Receptor in the Human Retina: A comparative study of diabetic and nondiabetic subjects Diabetes Care, June 1, 2008; 31(6): 1189 - 1194. [Abstract] [Full Text] [PDF]

				A. Bosco, D. M. Inman, M. R. Steele, G. Wu, I. Soto, N. Marsh-Armstrong, W. C. Hubbard, D. J. Calkins, P. J. Horner, and M. L. Vetter Reduced Retina Microglial Activation and Improved Optic Nerve Integrity with Minocycline Treatment in the DBA/2J Mouse Model of Glaucoma Invest. Ophthalmol. Vis. Sci., April 1, 2008; 49(4): 1437 - 1446. [Abstract] [Full Text] [PDF]

				B. P. Buckingham, D. M. Inman, W. Lambert, E. Oglesby, D. J. Calkins, M. R. Steele, M. L. Vetter, N. Marsh-Armstrong, and P. J. Horner Progressive Ganglion Cell Degeneration Precedes Neuronal Loss in a Mouse Model of Glaucoma J. Neurosci., March 12, 2008; 28(11): 2735 - 2744. [Abstract] [Full Text] [PDF]

				M. Scholz, T. Buder, S. Seeber, E. Adamek, C.-M. Becker, and E. Lutjen-Drecoll Dependency of Intraocular Pressure Elevation and Glaucomatous Changes in DBA/2J and DBA/2J-Rj Mice Invest. Ophthalmol. Vis. Sci., February 1, 2008; 49(2): 613 - 621. [Abstract] [Full Text] [PDF]

				J. Zhang, Y. Wu, Y. Jin, F. Ji, S. H. Sinclair, Y. Luo, G. Xu, L. Lu, W. Dai, M. Yanoff, et al. Intravitreal Injection of Erythropoietin Protects both Retinal Vascular and Neuronal Cells in Early Diabetes Invest. Ophthalmol. Vis. Sci., February 1, 2008; 49(2): 732 - 742. [Abstract] [Full Text] [PDF]

				I. Soto, E. Oglesby, B. P. Buckingham, J. L. Son, E. D. O. Roberson, M. R. Steele, D. M. Inman, M. L. Vetter, P. J. Horner, and N. Marsh-Armstrong Retinal Ganglion Cells Downregulate Gene Expression and Lose Their Axons within the Optic Nerve Head in a Mouse Glaucoma Model J. Neurosci., January 9, 2008; 28(2): 548 - 561. [Abstract] [Full Text] [PDF]

				M. Saleh, M. Nagaraju, and V. Porciatti Longitudinal Evaluation of Retinal Ganglion Cell Function and IOP in the DBA/2J Mouse Model of Glaucoma Invest. Ophthalmol. Vis. Sci., October 1, 2007; 48(10): 4564 - 4572. [Abstract] [Full Text] [PDF]

				K. Nishijima, Y.-S. Ng, L. Zhong, J. Bradley, W. Schubert, N. Jo, J. Akita, S. J. Samuelsson, G. S. Robinson, A. P. Adamis, et al. Vascular Endothelial Growth Factor-A Is a Survival Factor for Retinal Neurons and a Critical Neuroprotectant during the Adaptive Response to Ischemic Injury Am. J. Pathol., July 1, 2007; 171(1): 53 - 67. [Abstract] [Full Text] [PDF]